Key result
Paclitaxel prodrug-loaded synthetic high-density lipoprotein nanoparticles combined with anti-PD-L1 enhanced antitumor immunogenicity and intratumoral CD8 in TNBC.
Why the study?
Does P-sHDL combined with αPD-L1 enhance immunogenic cell death and intratumoral CD8 accumulation in triple-negative breast cancer?
Does P-sHDL combined with αPD-L1 enhance immunogenic cell death and intratumoral CD8 accumulation in triple-negative breast cancer?
Answers are grounded in this paper and cite their sources.
Paclitaxel prodrug-loaded synthetic HDL nanoparticles enhance immunogenic cell death and improve the efficacy of immune checkpoint blockade in triple-negative breast cancer models.
Insufficient tumor-specific immunogenicity and cytotoxic T lymphocytes infiltration limit the therapeutic efficacy of combined chemotherapy and immune checkpoint blockade for triple-negative breast cancer (TNBC). To address this limitation, we developed a paclitaxel prodrug-loaded synthetic high-density lipoprotein nanoparticle (P-sHDL) that both targets tumors and induces immunogenic cell death (ICD) to potentiate immune checkpoint blockade. Leveraging scavenger receptor class B type 1-mediated uptake, P-sHDL efficiently accumulated at tumor sites and triggered ICD in tumor cells, thereby enhancing antitumor immunogenicity. Building on this immunogenicity enhancement, P-sHDL was combined with an anti-programmed death-ligand 1 antibody (αPD-L1) to enhance intratumoral CD8
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied Triple-negative breast cancer (TNBC). Paclitaxel prodrug-loaded synthetic high-density lipoprotein nanoparticle (P-sHDL) and anti-PD-L1 was evaluated on Immunogenic cell death and intratumoral CD8 enhancement. Paclitaxel prodrug-loaded synthetic high-density lipoprotein nanoparticles combined with anti-PD-L1 enhanced antitumor immunogenicity and intratumoral CD8 in TNBC.
Synapse has enriched 10 related papers. Consider them for comparative context: